Metabolic labeling kinetics of brain-derived 24S-hydroxycholesterol in blood in multiple sclerosis: Effects of treatment with the remyelinating antibody rHIgM22
Plasma 24-OHC kinetics provide a minimally invasive biomarker of brain cholesterol metabolism and revealed differences between healthy and clinically stable MS subjects, with increased turnover of the metabolically active 24-OHC pool that normalized in response to rHIgM22 therapy.
Authors
- A. H. Eisen
- Scott Turner (ORCID: https://orcid.org/0000-0002-6618-6405)
- Edna Nyangau (ORCID: https://orcid.org/0000-0002-7430-3181)
- Marcy Matthews
- Hussein Mohammed (ORCID: https://orcid.org/0000-0002-9963-7129)
- Gordon I. Smith (ORCID: https://orcid.org/0000-0003-0063-046X)
- Marc K. Hellerstein (ORCID: https://orcid.org/0000-0002-2327-0834)
- Kelvin W. Li (ORCID: https://orcid.org/0000-0002-1771-1998)
- Mark Fitch (ORCID: https://orcid.org/0000-0001-9058-4529)
- Samuel Klein (ORCID: https://orcid.org/0000-0001-5786-7113)
- Joan Protasio
- Mahalakshmi Shankaran (ORCID: https://orcid.org/0000-0001-9138-9610)
Institutions
- Washington University in St. Louis (US)
- Acorda Therapeutics (United States) (US)
- KineMed (United States) (US)
- University of California, Berkeley (US)
Publication Details
- Journal
- Multiple Sclerosis Journal - Experimental Translational and Clinical
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1177/20552173251344555
- Citations
- 2
- Primary Topic
- Cholesterol and Lipid Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Academy of Nutrition and Dietetics Foundation
- Pershing Square Foundation
- KineMed
- Acorda Therapeutics
- National Institutes of Health